Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2311-2315

  Chu, Huili ^a   Zhong, Chen ^a   Xue, Guoliang ^a   Liang, Xiuju ^a   Wang, Jun ^a   Liu, Yingxin ^a   Zhao, Shiwei ^a   Zhou, Qian ^b   Bi, Jingwang ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

ADx ARMS; Direct sequencing; EGFR mutation; Malignant pleural effusion; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ADULT; ANALYTIC METHOD; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; DIRECT SEQUENCING; DNA SEQUENCE; DRUG EFFICACY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; LUNG FLUID; LUNG NON SMALL CELL CANCER; MALE; MALIGNANT PLEURA EFFUSION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA;

EID: 84885043173     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2709     Document Type: Article

References (25)

1. No authors listed: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311: 899-909, 1995.
2. Haura EB: Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control 8: 326-336, 2001.
3. Schiller JH: Current standards of care in small-cell and non-small-cell lung cancer. Oncology 61 (Suppl 1): 3-13, 2001.
4. Ohsaki Y, Tanno S, Fujita Y, et al: Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 7: 603-607, 2000.
5. Nicholson RI, Gee JM and Harper ME: EGFR and cancer prognosis. Eur J Cancer 37 (Suppl 4): 9-15, 2001.
6. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
7. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
8. Han SW, Kim TY, Hwang PG, et al: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493-2501, 2005.
9. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005.
10. Carey KD, Garton AJ, Romero MS, et al: Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 66: 8163-8171, 2006.
11. Borras E, Jurado I, Hernan I, Gamundi MJ, Dias M, Marti I, Mane B, Arcusa A, Agundez JA, Blanca M and Carballo M: Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer 11: 406, 2011.
12. Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742, 2011.
13. Fenton KN and Richardson JD: Diagnosis and management of malignant pleural effusions. Am J Surg 170: 69-74, 1995.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
15. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 22: 777-784, 2004.
16. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 22: 785-794, 2004.
17. Jian G, Songwen Z, Ling Z, et al: Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol 136: 1341-1347, 2010.
18. Bosari S, Marchetti A, Buttitta F, et al: Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis. A comparative study of radioactive and nonradioactive silver-stained SSCP analysis. Diagn Mol Pathol 4: 249-255, 1995.
19. Fan X, Furnari FB, Cavenee WK, et al: Non-isotopic silver-stained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells. Int J Oncol 18: 1023-1026, 2001.
20. Kimura H, Fujiwara Y, Sone T, et al: EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer 95: 1390-1395, 2006.
21. Kimura H, Kasahara K, Kawaishi M, et al: Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12: 3915-3921, 2006.
22. Kubo A, Koh Y, Kawaguchi T, et al: Malignant pleural effusion from lung adenocarcinoma treated by gefitinib. Intern Med 50: 745-748, 2011.
23. Zhang X, Zhao Y, Wang M, et al: Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer. Lung Cancer 60: 175-182, 2008.
24. Han HS, Lim SN, An JY, et al: Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity. J Thorac Oncol 7: 355-364, 2012.
25. Tsai TH, Wu SG, Chang YL, et al: Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma. J Thorac Oncol 7: 993-1000, 2012.